Vascular calcification and ESRD: A hard target

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue SUPPL. 1, 2009, Pages

  Bhan, Ishir ^a   Thadhani, Ravi ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM ACETATE; FIBROBLAST GROWTH FACTOR 23; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; KLOTHO PROTEIN; LANTHANUM; OXYGENASE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; RECEPTOR BLOCKING AGENT; SEVELAMER; SODIUM THIOSULFATE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR BLOCKING AGENT;

ARTERIAL STIFFNESS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DIET THERAPY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MINERAL METABOLISM; MORTALITY; NONHUMAN; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

CALCINOSIS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; TREATMENT OUTCOME; VASCULAR DISEASES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 73849083538     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04800709     Document Type: Conference Paper

References (38)

1. Keelan PC, Bielak LF, Ashai K, Jamjoum LS, Denktas AE, Rumberger JA, Sheedy II PF, Peyser PA, Schwartz RS: Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation 104: 412-417, 2001
2. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218-223, 2000
3. London GM: Cardiovascular calcifications in uremic patients: Clinical impact on cardiovascular function. J Am Soc Nephrol 14: S305-S309, 2003
4. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
5. Stompó r TP, Pasowicz M, Sulowicz W, Dembiń ska-Kieć A, Janda K, Wó jcik K, Tracz W, Zdzienicka A, Konieczyń ska M, Klimeczek P, Janusz-Grzybowska E: Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. Am J Kidney Dis 44: 517-528, 2004
6. Yuen D, Pierratos A, Richardson RM, Chan CT: The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. Nephrol Dial Transplant 21: 1407-1412, 2006
7. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1824, 2005
8. Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM: Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 63: 1852-1860, 2003
9. Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P: Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. Hypertension 49: 1278-1284, 2007
10. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938-942, 2001
11. Okuno S, Ishimura E, Kitatani K, Fujino Y, Kohno K, Maeno Y, Maekawa K, Yamakawa T, Imanishi Y, Inaba M, Nishizawa Y: Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 49: 417-425, 2007
12. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-441, 2007
13. DeLoach SS, Joffe MM, Mai X, Goral S, Rosas SE: Aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation. Nephrol Dial Transplant 24: 1314-1319, 2009
14. Maizel J, Six I, Slama M, Tribouilloy C, Sevestre H, Poirot S, Giummelly P, Atkinson J, Choukroun G, Andrejak M, Kamel S, Mazière JC, Massy ZA: Mechanisms of aortic and cardiac dysfunction in uremic mice with aortic calcification. Circulation 119: 306-313, 2009
15. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA: Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19: 1509-1519, 2008
16. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Kidney Int 72: 709-715, 2007
17. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96: 1755-1760, 1997
18. Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees L: A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 19: 1239-1246, 2008
19. Cardú s A, Panizo S, Parisi E, Fernandez E, Valdivielso JM: Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22: 860-866, 2007
20. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003
21. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS: 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 20: 1805-1812, 2009
22. Andress D: Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int 69: 33-43, 2006
23. Zittermann A, Schleithoff SS, Koerfer R: Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 94: 483-492, 2005
24. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997
25. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y: Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17: 2393-2403, 2003
26. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD: Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18: 2116-2124, 2007
27. Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M: Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20: 388-396, 2009
28. Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD: The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23: 307-314, 2003
29. Chertow GM, Burke SK, Raggi P, Group TtGW: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
30. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B, Network AKD: Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 22: 2856-2866, 2007
31. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M: Investigators CARE-. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51: 952-965, 2008
32. Suki W, Zabaneh R, Cangiano J, Reed J, Fischer D, Garrett L, Ling B, Chasan-Taber S, Dillon M, Blair A, Burke S: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130-1137, 2007
33. Zhou YB, Jin SJ, Cai Y, Teng X, Chen L, Tang CS, Qi YF: Lanthanum acetate inhibits vascular calcification induced by vitamin D3 and nicotine in rats. Exp Biol Med (Maywood) 234: 908-917, 2009
34. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M: The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 73: 300-307, 2008
35. Vitamin D and Coronary Calcification Study (VCOR). Available at http://www.clinicaltrials.gov/ct2/show/NCT00752102. Accessed August 31, 2009
36. ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis. Available at http:// www.clinicaltrials.gov/ct2/show/NCT00379899. Accessed August 31, 2009
37. Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease. Available at http://www.clinicaltrials. gov/ct2/show/NCT00395382. Accessed August 31, 2009
38. Sodium Thiosulfate Treatment of Vascular Calcification in ESRD. Available at http://www.clinicaltrials.gov/ct2/show/NCT00568399. Accessed August 31, 2009